AU Patent

AU2018208694A1 — Pharmaceutical compositions of (R)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methypropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide and administration thereof

Assigned to Vertex Pharmaceuticals Inc · Expires 2018-08-09 · 8y expired

What this patent protects

A pharmaceutical composition comprising Compound 1, (R)- 1 -(2,2 difluorobenzo[d] [1,3]dioxol-5-yl)-N-(1 -(2,3 -dihydroxypropyl)-6-fluoro-2-(1 -hydroxy-2 methylpropan-2-yl)- 1 H-indol-5-yl)cyclopropanecarboxamide, and at least one excipient selected from: a filler, a disintegrant…

USPTO Abstract

A pharmaceutical composition comprising Compound 1, (R)- 1 -(2,2 difluorobenzo[d] [1,3]dioxol-5-yl)-N-(1 -(2,3 -dihydroxypropyl)-6-fluoro-2-(1 -hydroxy-2 methylpropan-2-yl)- 1 H-indol-5-yl)cyclopropanecarboxamide, and at least one excipient selected from: a filler, a disintegrant, a surfactant, a glidant and a lubricant, the composition being suitable for oral administration to a patient in need thereof to treat a CFTR mediated disease such as Cystic Fibrosis. Methods for treating a patient in need thereof include administering the pharmaceutical composition of Compound 1 are also disclosed.

Drugs covered by this patent

Patent Metadata

Patent number
AU2018208694A1
Jurisdiction
AU
Classification
—
Expires
2018-08-09
Drug substance claim
No
Drug product claim
No
Assignee
Vertex Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.